MARTIN STOLTENBERG: Open Payments
NPI 1730303157 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,252 in 91 payments from 13 companies in 2025. Trend: 2023 $1,145 · 2024 $1,260 · 2025 $2,252
Food & beverage: $2,249Education: $4
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $673 |
| Vanda Pharmaceuticals Inc. | 18 | $410 |
| Axsome Therapeutics, Inc. | 9 | $373 |
| ABBVIE INC. | 19 | $371 |
| Supernus Pharmaceuticals, Inc. | 7 | $173 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 3 | $53 |
| Noven Therapeutics, LLC | 3 | $43 |
| Lundbeck LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
Products named: CAPLYTA, Auvelity, VRAYLAR, FANAPT, Qelbree, HETLIOZ, REXULTI, COBENFY.
Industry payments across NE — which companies pay providers there.
